Shandong Xiansheng Maidejin Biopharmaceutical

Simcere Medigene is a specialized biopharmaceutical subsidiary of Simcere Pharmaceutical Group, primarily focused on oncology and anti-angiogenic therapy. The company's flagship product, Endostar (recombinant human endostatin), was the first anti-angiogenic targeted drug developed in China and is widely used in the treatment of non-small cell lung cancer. Simcere Medigene maintains advanced manufacturing facilities in Yantai, Shandong, capable of large-scale production of recombinant proteins. The company continues to expand the clinical applications of its core technology through studies in malignant effusions and combination regimens with chemotherapy and immunotherapy.